Arformoterol: Difference between revisions

Latest revision as of 11:37, 23 March 2025

A long-acting beta-adrenoceptor agonist used in the treatment of chronic obstructive pulmonary disease

Arformoterol is a long-acting beta-adrenoceptor agonist (LABA) used in the management of chronic obstructive pulmonary disease (COPD). It is the (R,R)-enantiomer of formoterol, which is responsible for the drug's bronchodilatory effects. Arformoterol is marketed under the brand name Brovana and is administered via inhalation.

Pharmacology[edit]

Arformoterol works by stimulating beta-2 adrenergic receptors in the bronchial smooth muscle, leading to muscle relaxation and bronchodilation. This action helps to alleviate symptoms of COPD such as shortness of breath and wheezing.

Mechanism of Action[edit]

The drug binds to beta-2 adrenergic receptors, which are G protein-coupled receptors located on the surface of bronchial smooth muscle cells. Upon activation, these receptors initiate a cascade of intracellular events that result in the relaxation of smooth muscle fibers, thereby dilating the airways and improving airflow.

Pharmacokinetics[edit]

Arformoterol is administered via inhalation, allowing for direct delivery to the lungs. It has a rapid onset of action, typically within 20 minutes, and its effects can last up to 12 hours, making it suitable for twice-daily dosing. The drug is metabolized primarily in the liver and excreted in the urine.

Clinical Use[edit]

Arformoterol is indicated for the long-term maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema. It is not intended for the relief of acute bronchospasm or for the treatment of asthma.

Side Effects[edit]

Common side effects of arformoterol include tremor, nervousness, and headache. As with other beta-agonists, it may cause cardiovascular effects such as increased heart rate and blood pressure. Patients should be monitored for signs of worsening asthma or paradoxical bronchospasm.

Illustration of Skeletal Muscle[edit]

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Arformoterol''' is a long-acting [[beta2-adrenergic receptor agonist]] (LABA) used in the management of [[chronic obstructive pulmonary disease]] (COPD). It is a [[stereoisomer]] of [[formoterol]], specifically the (R,R)-enantiomer, which is believed to be the active form of the drug. Arformoterol works by relaxing the muscles in the airways and widening the airways in the lungs, which helps to improve breathing in individuals with COPD. It is administered through nebulization, making it suitable for patients who may have difficulties with handheld inhalers.
+{{Short description|A long-acting beta-adrenoceptor agonist used in the treatment of chronic obstructive pulmonary disease}}
-==Mechanism of Action==
+[[File:Arformoterol.svg|Chemical structure of Arformoterol|thumb|right]]
-Arformoterol acts on the beta2-adrenergic receptors located in the smooth muscle of the airways. Activation of these receptors leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels, resulting in bronchial smooth muscle relaxation and bronchodilation. This action reduces airway resistance and facilitates airflow, thereby alleviating symptoms of bronchospasm, wheezing, and shortness of breath in COPD patients.
-==Indications==
+'''Arformoterol''' is a [[long-acting beta-adrenoceptor agonist]] (LABA) used in the management of [[chronic obstructive pulmonary disease]] (COPD). It is the (R,R)-enantiomer of [[formoterol]], which is responsible for the drug's bronchodilatory effects. Arformoterol is marketed under the brand name Brovana and is administered via inhalation.
-Arformoterol is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema. It is not intended for the relief of acute symptoms of COPD or for the treatment of asthma, as its safety and efficacy have not been established in these conditions.
-==Contraindications and Precautions==
+==Pharmacology==
-Arformoterol is contraindicated in patients with a history of hypersensitivity to arformoterol, formoterol, or any of its components. It should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension, due to the potential for increased heart rate, blood pressure, and cardiovascular effects associated with beta2-adrenergic agonists.
+Arformoterol works by stimulating [[beta-2 adrenergic receptors]] in the [[bronchial smooth muscle]], leading to muscle relaxation and bronchodilation. This action helps to alleviate symptoms of COPD such as shortness of breath and wheezing.
-==Side Effects==
+[[File:Arformoterol_ball-and-stick_model.png|Ball-and-stick model of Arformoterol|thumb|left]]
-Common side effects of arformoterol include headache, tremor, dry mouth, and insomnia. Less frequently, it can cause palpitations, chest pain, and hypokalemia. As with other LABAs, there is a risk of asthma-related death when used in patients with asthma without a concomitant inhaled corticosteroid.
+===Mechanism of Action===
+The drug binds to beta-2 adrenergic receptors, which are G protein-coupled receptors located on the surface of bronchial smooth muscle cells. Upon activation, these receptors initiate a cascade of intracellular events that result in the relaxation of smooth muscle fibers, thereby dilating the airways and improving airflow.
+===Pharmacokinetics===
+Arformoterol is administered via inhalation, allowing for direct delivery to the lungs. It has a rapid onset of action, typically within 20 minutes, and its effects can last up to 12 hours, making it suitable for twice-daily dosing. The drug is metabolized primarily in the liver and excreted in the urine.
-==Drug Interactions==
+==Clinical Use==
-Arformoterol may interact with other medications, including beta-blockers, which can reduce its effectiveness, and diuretics, which can exacerbate hypokalemia. Caution should be exercised when prescribing arformoterol with other medications that prolong the QT interval or within 2 weeks of discontinuing monoamine oxidase inhibitors or tricyclic antidepressants.
+Arformoterol is indicated for the long-term maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema. It is not intended for the relief of acute bronchospasm or for the treatment of asthma.
-==Pharmacokinetics==
+==Side Effects==
-Arformoterol is rapidly absorbed following inhalation and has a plasma half-life of approximately 26 hours, supporting its twice-daily dosing regimen. It is primarily metabolized by conjugation and excreted in the urine and feces.
+Common side effects of arformoterol include tremor, nervousness, and headache. As with other beta-agonists, it may cause cardiovascular effects such as increased heart rate and blood pressure. Patients should be monitored for signs of worsening asthma or paradoxical bronchospasm.
-==Conclusion==
+==Illustration of Skeletal Muscle==
-Arformoterol is an effective long-acting beta2-adrenergic agonist for the maintenance treatment of COPD. Its long half-life allows for convenient twice-daily dosing. However, it should be used with caution in certain patient populations and is not suitable for the treatment of acute bronchospasm or asthma.
+[[File:Blausen_0801_SkeletalMuscle.png|Illustration of skeletal muscle|thumb|right]]
-[[Category:Respiratory system drugs]]
+==Related Pages==
-[[Category:Beta2-adrenergic agonists]]
+* [[Formoterol]]
+* [[Beta-2 adrenergic receptor]]
+* [[Chronic obstructive pulmonary disease]]
+* [[Bronchodilator]]
-{{Pharmacology-stub}}
+[[Category:Beta-2 adrenergic agonists]]
+[[Category:Drugs used in respiratory diseases]]